Indocyanine Hydrate Crystal Formation for Stability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing indocyanine compounds are amorphous and lack a defined crystal form, which affects their stability and applicability in medical and diagnostic applications.
Innovation Solution
Controlled humidity conditions and specific preparation methods are employed to obtain crystals of indocyanine compounds, characterized by distinct X-ray diffraction peaks, with varying water molecule content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If indocyanine compounds are prepared using conventional methods, then they can be obtained as amorphous solids or inclusion compounds, but they lack defined crystal form which affects stability and applicability
Solution Approach 1:
The patent applies parameter changes by controlling humidity levels and temperature conditions during the preparation process. Specifically, the compound is prepared at controlled humidity (40-95% RH) and temperature (0-5°C), which transforms the product from amorphous solid to defined crystal form with specific X-ray diffraction peaks, thereby resolving the contradiction between ease of manufacture and crystal stability.
Solution Approach 2:
The patent utilizes phase transitions by controlling the physical state changes of the indocyanine compound during crystallization. The compound transitions from an amorphous solid phase to a crystalline phase through controlled humidity and temperature conditions, resulting in a stable crystal form with defined molecular arrangement and characteristic diffraction peaks.
2Stability of the object's composition
If controlled humidity conditions are applied to obtain crystals, then crystal form and stability are improved, but process complexity increases
Solution Approach 1:
The patent employs parameter changes by establishing specific humidity (40-95% RH) and temperature (0-5°C) ranges that enable crystal formation without requiring complex equipment. The method uses simple environmental control parameters that can be implemented with basic laboratory equipment, resolving the contradiction between achieving defined crystal form and maintaining process simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Stable crystal forms of indocyanine compounds are achieved, enhancing their suitability for medical diagnostics and pharmaceutical applications by maintaining structural integrity and functionality.
Implementation Method 1
The inventors also found the state of the crystal form was related to an amount of water (H2O) molecules. Specifically, it is the following: A crystal of 3-(3-{[3-(cyclomaltoheptaos-21-O-yl)propyl]amino}-3-oxopropyl)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3-{[3-(cyclomaltoheptaos-21-O-yl)propyl]amino}-3-oxopropyl)-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-ylidene]ethylidene}-2-methoxycyclohex-1-en-1-yl]ethen-1-yl}-1,1-dimethyl-1H-benzo[e]indol-3-ium chloride having 10 to 45 mol of water molecule.
Implementation Method 2
The crystal according to [1], wherein in the powder X-ray analysis using Cu as a radiation source, 2θ (°) exhibits peaks at around 3.7, around 6.1, around 6.3, around 7.0, around 7.7, around 9.6, around 12.4, around 12.5, around 12.7, around 18.5, and around 18.8.
Data Source
AI summary
The present invention is a crystal of 3-(3-{[3-(cyclomaltoheptaos-21-O-yl)propyl]amino}-3-oxopropyl)-2-{(1E)-2-[(3E)-3-{(2E)-2-[3-(3-{[3-(cyclomaltoheptaos-21-O-yl)propyl]amino}-3-oxopropyl)-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-ylidene]ethylidene}-2-methoxycyclohex-1-en-1-yl]ethen-1-yl}-1,1-dimethyl-1H-benzo[e]indol-3-ium chloride.